Protocol Ledger

NCT06355479 · Phase III · COMPLETED

A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia

Interventional Phase III clinical trial protocol NCT06355479 sponsored by Healthgen Biotechnology in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-04-10 Enrollment: 328 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06355479
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)328 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06355479
Protocol FieldVerified Registry Value
NCT IdentifierNCT06355479
Consolidated Lead SponsorHealthgen Biotechnology
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment328 participants (ACTUAL)
Registered Start Date2023-04-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI